A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Results from CYCLONE 1.
Archana M AgarwalDaniel CastellanoTeresa Alonso GordoaJose Angel Arranz ArijaEmeline ColombaGwenaëlle GravisLoic MoureyStephane Marie OudardAude FlechonMacarena GonzálezPablo M ReyMichael Thomas SchweizerEnrique GallardoErica JohnstonArjun V BalarNadine HaddadAdams K AppiahKarim NacerddineJosep Maria PiulatsPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Abemaciclib monotherapy was well tolerated and showed clinical activity in this heavily pretreated population, nearly half with visceral metastases. This study is considered preliminary proof-of-concept and designates CDK4/6 as a valid therapeutic target in prostate cancer.